Company profile
Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06848348 | phase2 | recruiting | 2025-02-21 | 2026-07-01 | Dogwood Therapeutics Inc. | Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain |
FDA applications (0)
No records yet.